SCHEMBL5954486

SCHEMBL5954486

C=CCN1C(=O)C(C)N(c2ccc(OCc3ccccc3)cc2)C1=S

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT1 Q96EB6 4/20 0.49
SIRT5 Q9NXA8 4/20 0.49
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
NR1H4 Q96RI1 1/20 0.41
KDM4C Q9H3R0 1/20 0.41
SIRT2 Q8IXJ6 3/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
SIRT3 Q9NTG7 1/20 0.41
PKM P14618 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MAOB P27338 1/20 0.40
APOBEC3G Q9HC16 1/20 0.39
GRM2 Q14416 1/20 0.39
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5955106 0.85 HTT (0.39) SIRT1SIRT5MEN1KMT2AL3MBTL1
SCHEMBL5954451 0.83 MEN1 (0.44) SIRT1SIRT5MEN1KMT2ANR1H4
SCHEMBL5955227 0.81 NPC1 (0.47) MEN1KMT2ANR1H4KDM4CNPC1
SCHEMBL5955334 0.81 NPC1 (0.47) MEN1KMT2ANR1H4KDM4CNPC1
SCHEMBL5955048 0.78 MEN1 (0.47) MEN1KMT2AKDM4CNPC1RAB9A
SCHEMBL5954521 0.77 SMO (0.51) MEN1KMT2AKDM4CNPC1RAB9A
SCHEMBL5955353 0.76 SIRT1 (0.52) SIRT1SIRT5NR1H4SIRT2NPC1
SCHEMBL5955021 0.75 MEN1 (0.40) MEN1KMT2AL3MBTL1ALDH1A1MAPT
SCHEMBL6169897 0.72 SIRT1 (0.55) SIRT1SIRT5MEN1KMT2AKDM4C
SCHEMBL5955056 0.72 LMNA (0.40) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060025589-A1 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes LABORATOIRES FOURNIER S.A. (FR) 2006-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025589-A1 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes LIPC, CYP4F2, SLC5A2 SIRT1 2353/4885SIRT5 2180/4885MEN1 3372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.